PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y. Ng, Raphael Koch, Noriaki Yoshida et al.|Nature Communications|2018Cited by 114
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|The Lancet Oncology|2021Cited by 102
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Mohammad Omaira et al.|The Lancet Haematology|2019Cited by 72
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J. Frigault, Robin Joyce, Philippe Armand et al.|Blood Advances|2020Cited by 65